share_log

沛嘉医疗-B(09996)上半年收入同比增加约85.2%-93.6%至约2.2亿-2.3亿元

The revenue of Peijia Medical-B (09996) in the first half of the year increased by about 85.2%-93.6% year-on-year to about 220 million to 230 million yuan

Zhitong Finance ·  07/21/2023 18:07

Zhitong Financial App News, Peijia Medical-B (09996) issued an announcement that the company's revenue for the six months ended June 30, 2023 increased by about 85.2% RMB93.6% to about RMB 220 million-230 million.

The increase in revenue is mainly due to the following reasons: group transcatheter aortic valve replacement products (including the first generation product TaurusOne), the announcement said.And the second generation recyclable product TaurusElite) accelerate commercialization and further expand market share; the Group's existing neural intervention products (including TethysIntermediate guide catheter, SacSpeedBalloon dilation catheter, JasperIntracranial Electrolytic detachable coils and SyphonetThrombectomy stents, etc.) continue to contribute to the group's revenue growth; and the ischemic products (including Fastunnel) approved by the State Drug Administration for registration in the second quarter of 2022Transport balloon dilatation catheter, etc.) began to be commercialized, contributing to the group's revenue growth.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment